Phase Ib Study: Lenvatinib + Pembrolizumab in Unresectable Hepatocellular Carcinoma

June 1-5, 2018; Chicago, Illinois
Lenvatinib combined with pembrolizumab showed promising antitumor activity with no unexpected toxicities in this early-stage study.
Format: Microsoft PowerPoint (.ppt)
File Size: 239 KB
Released: June 7, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Virtual presentation by Shannon N. Westin, MD, MPH, on improving health equity for patients with endometrial cancer, from Clinical Care Options (CCO)

Shannon N. Westin, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 17, 2021 Expired: September 16, 2022

Global perspective of key studies presented at ASCO, EHA, ICML 2021 from an international expert in CLL from Clinical Care Options (CCO)

George Follows, BM, BCh, PhD Released: September 17, 2021

Download these slides for an overview of the evolving immunotherapy landscape for advanced or metastatic NSCLC, from CCO

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Download these slides for an overview of the evolving immunotherapy landscape for early-stage resectable and stage III unresectable NSCLC, from CCO

person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue